论文部分内容阅读
金杜律师事务所:你所报送的《关于亿胜生物科技有限公司在境外发行股票和上市的法律意见书》收悉。经审阅,函复如下:该法律意见书陈述的主要事实和意见如下:一、亿胜生物科技有限公司(Essex Bio-Technology Limited,简称“亿胜生物”)于2000年7月在开曼注册成立,控股股东 EssexHoldings Limited(注册地香港)持股75%;另有6个新加坡公民持有该公司的股份,他们均未曾取得境内居民身份。二、亿胜生物通过 Essex Bio-PharmacyLimited(简称“亿胜制药”)间接持有境内外商投资企业珠海亿胜生物制药有限公司(简称“珠海亿胜”)和深圳亿胜医药科技发展有限
King & Wood LLP: You have received the “Legal Opinion on the Issuance of Stocks and the Listing of Stocks by Billion Sheng Biotech Co., Ltd.”. Upon review, the reply is as follows: The major facts and views stated in the legal opinion statement are as follows: 1. Essex Bio-Technology Limited (“Billion Sheng Bio”) was opened in July 2000 Man incorporated, the controlling shareholder of Essex Holdings Limited (registered in Hong Kong) 75% stake; and another six Singaporean citizens to hold the shares of the company, they did not obtain the identity of domestic residents. Second, Bison wins the indirect holding of Zhuhai Yisheng Bio-Pharmaceutical Co., Ltd. (Zhuhai Yisheng Bio-Pharmaceutical Co., Ltd.) by foreign-invested enterprises in China and Essex Bio-Pharmacy Limited (“Billion Pharmaceuticals” Limited development